Glenmark Pharmaceuticals Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – 2016’, provides an overview of the Glenmark Pharmaceuticals Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Glenmark Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Glenmark Pharmaceuticals Ltd.

The report provides overview of Glenmark Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Glenmark Pharmaceuticals Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Glenmark Pharmaceuticals Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Glenmark Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glenmark Pharmaceuticals Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glenmark Pharmaceuticals Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Glenmark Pharmaceuticals Ltd. Snapshot 5

Glenmark Pharmaceuticals Ltd. Overview 5

Key Information 5

Key Facts 5

Glenmark Pharmaceuticals Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

Glenmark Pharmaceuticals Ltd. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Glenmark Pharmaceuticals Ltd. - Pipeline Products Glance 13

Glenmark Pharmaceuticals Ltd. - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Glenmark Pharmaceuticals Ltd. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Glenmark Pharmaceuticals Ltd. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Glenmark Pharmaceuticals Ltd. - Drug Profiles 17

crofelemer DR 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

GSP-301 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

GBR-830 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

GRC-17536 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

GBR-1302 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

GBR-900 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

GRC-27864 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

GBR-1342 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

GBR-600 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule to Antagonize TRPM8 for Neuropathic Pain 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Glenmark Pharmaceuticals Ltd. - Pipeline Analysis 29

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Target 29

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 31

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 32

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 33

Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates 35

Glenmark Pharmaceuticals Ltd. - Dormant Projects 40

Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products 41

Discontinued Pipeline Product Profiles 41

GRC-15300 41

GRC-6211 41

oglemilast 41

revamilast 41

Glenmark Pharmaceuticals Ltd. - Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

Glenmark Pharmaceuticals Ltd., Key Information 5

Glenmark Pharmaceuticals Ltd., Key Facts 5

Glenmark Pharmaceuticals Ltd. – Pipeline by Indication, 2016 8

Glenmark Pharmaceuticals Ltd. – Pipeline by Stage of Development, 2016 9

Glenmark Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, 2016 10

Glenmark Pharmaceuticals Ltd. – Partnered Products in Pipeline, 2016 11

Glenmark Pharmaceuticals Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 12

Glenmark Pharmaceuticals Ltd. – Phase III, 2016 13

Glenmark Pharmaceuticals Ltd. – Phase II, 2016 14

Glenmark Pharmaceuticals Ltd. – Phase I, 2016 15

Glenmark Pharmaceuticals Ltd. – Preclinical, 2016 16

Glenmark Pharmaceuticals Ltd. – Pipeline by Target, 2016 30

Glenmark Pharmaceuticals Ltd. – Pipeline by Route of Administration, 2016 31

Glenmark Pharmaceuticals Ltd. – Pipeline by Molecule Type, 2016 32

Glenmark Pharmaceuticals Ltd. – Pipeline Products by Mechanism of Action, 2016 34

Glenmark Pharmaceuticals Ltd. – Recent Pipeline Updates, 2016 35

Glenmark Pharmaceuticals Ltd. – Dormant Developmental Projects,2016 40

Glenmark Pharmaceuticals Ltd. – Discontinued Pipeline Products, 2016 41

Glenmark Pharmaceuticals Ltd., Subsidiaries 42

List of Figures

List of Figures

Glenmark Pharmaceuticals Ltd. – Pipeline by Top 10 Indication, 2016 7

Glenmark Pharmaceuticals Ltd. – Pipeline by Stage of Development, 2016 9

Glenmark Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, 2016 10

Glenmark Pharmaceuticals Ltd. – Partnered Products in Pipeline, 2016 11

Glenmark Pharmaceuticals Ltd. – Pipeline by Top 10 Target, 2016 29

Glenmark Pharmaceuticals Ltd. – Pipeline by Route of Administration, 2016 31

Glenmark Pharmaceuticals Ltd. – Pipeline by Molecule Type, 2016 32

Glenmark Pharmaceuticals Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports